Oritavancin Monotherapy for the Treatment of vanA Vancomycin-Resistant Enterococcus faecium Infections: A Case Series from a Referral Hospital
Antibiotics · 17.11.2026 · 15 (11) · 1146
DOI: 10.3390/antibiotics15111146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 17.11.2026. Verfasst von Joan Roig-Sanchis und 10 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vancomycin-resistant Enterococcus faecium (VREfm) infection treatment remains challenging. Oritavancin is active against vanA-VREfm, but clinical evidence is limited to case reports or combined treatments. This study aims to describe the characteristics and outcomes of vanA-VREfm infections treated with oritavancin monotherapy.
Methods
We conducted a retrospective, single-center study at a tertiary hospital in Spain, including all adults treated with oritavancin monotherapy for vanA-VREfm infections (January 2024–December 2025). Oritavancin was administered as a 1200-mg initial dose, with weekly doses as needed. Primary outcomes were 30-day all-cause mortality and clinical failure. Secondary outcomes included 90-day mortality, relapse, microbiological recurrence, and adverse events. Susceptibility was determined by commercial broth microdilution (ComASP® Oritavancin 0.001-16, Liofilchem s.r.l.) according to CLSI criteria.
Results
Ten patients received oritavancin, and seven fulfilled the inclusion criteria. The median age was 55 years (IQR 44.5–69), and the median age-adjusted Charlson comorbidity index was 7 (IQR 7–7.5). The most common source of infection was the urinary tract (n = 3). Three patients had bacteremia. All vanA-VREfm isolates were susceptible to oritavancin. Five patients had co-infection with another microorganism at the time of VREfm infection diagnosis. Three patients had a drainable focus, and all underwent source control. The median duration of oritavancin therapy was 21 days (IQR 7–42). None of the patients experienced clinical failure on day 30. The only death within 90 days was attributable to progression of underlying disease. One patient experienced an infusion-related adverse event of vomiting and shivering. No infection relapses or microbiological recurrences were observed within three months.
Conclusions
In this small cohort, oritavancin monotherapy appeared to be safe and effective for treating vanA VREfm infections.
Zitieren
APA
Roig-Sanchis, J., Barrio-Tofiño, E. D., Los-Arcos, I., Fernández-Hidalgo, N., Campany, D., Viñado, B., Sellarès-Nadal, J., Albasanz-Puig, A., Kirkegaard-Biosca, C., Larrosa, N., & Rodríguez-Pardo, D. (2026). Oritavancin Monotherapy for the Treatment of vanA Vancomycin-Resistant Enterococcus faecium Infections: A Case Series from a Referral Hospital. Antibiotics, 15(11), 1146. https://doi.org/10.3390/antibiotics15111146
Vancouver
Roig-Sanchis J, Barrio-Tofiño ED, Los-Arcos I, Fernández-Hidalgo N, Campany D, Viñado B, et al. Oritavancin Monotherapy for the Treatment of vanA Vancomycin-Resistant Enterococcus faecium Infections: A Case Series from a Referral Hospital. Antibiotics. 2026;15(11):1146. doi:10.3390/antibiotics15111146
BibTeX
@article{RoigSanchis2026,
author = {Roig-Sanchis, Joan and Barrio-Tofiño, Ester del and Los-Arcos, Ibai and Fernández-Hidalgo, Nuria and Campany, David and Viñado, Belén and Sellarès-Nadal, Julia and Albasanz-Puig, Adaia and Kirkegaard-Biosca, Cristina and Larrosa, Nieves and Rodríguez-Pardo, Dolors},
title = {Oritavancin Monotherapy for the Treatment of vanA Vancomycin-Resistant Enterococcus faecium Infections: A Case Series from a Referral Hospital},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {11},
pages = {1146},
doi = {10.3390/antibiotics15111146}
}
EUVIMED